Application of Immuno-PET in Antibody–Drug Conjugate Development
Molecular Imaging, 2018 Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective ...
Kendra S. Carmon PhD, Ali Azhdarinia PhD
doaj +1 more source
A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET
EJNMMI Radiopharmacy and Chemistry, 2022 Background Pretargeted immuno-PET tumor imaging has emerged as a valuable diagnostic strategy that combines the high specificity of antibody-antigen interaction with the high signal and image resolution offered by short-lived PET isotopes, while reducing
Hugo Helbert +11 more
doaj +1 more source
Immuno-PET of epithelial ovarian cancer: Harnessing the potential of CA125 for non-invasive imaging [PDF]
, 2014 BACKGROUND: Epithelial ovarian cancer (EOC) is characterized by the overexpression of cancer antigen 125 (CA125), a mucinous glycoprotein that serves as a tumor biomarker.
Andrais, Bonnie +6 more
core +2 more sources
Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]
, 2016 With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S. +6 more
core +2 more sources
Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice. [PDF]
PLoS ONE, 2017 The purpose of this work was to use various molecular imaging techniques to non-invasively assess GSK2849330 (anti HER3 ADCC and CDC enhanced 'AccretaMab' monoclonal antibody) pharmacokinetics and pharmacodynamics in human xenograft tumor-bearing mice ...
Hasan Alsaid +12 more
doaj +1 more source
EJNMMI Research, 2023 Background Early intrahepatic recurrence is common after surgical resection of hepatocellular carcinoma (HCC) and leads to increased morbidity and mortality.
Kevin P. Labadie +13 more
doaj +1 more source
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
Frontiers in Immunology, 2023 BackgroundHarnessing the anti-tumor immune system response by targeting the program cell death protein (PD-1) and program cell death ligand protein (PD-L1) axis has been a major breakthrough in non-small cell lung cancer (NSCLC) therapy.
Ander Puyalto +36 more
doaj +1 more source
Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling [PDF]
, 2016 BACKGROUND: We applied a non-linear immunokinetic model to quantitatively compare absolute antibody uptake and turnover in subcutaneous LNCaP human prostate cancer (PCa) xenografts of two radiolabeled forms of the humanized anti-prostate-specific ...
Blesida Punzalan +13 more
core +1 more source
Optimization of cyclotron production for radiometal of Zirconium 89 [PDF]
, 2015 Zirconium 89 (89Zr) is a promising radionuclide for development of new PET agents due to its convenient half life of 78.4 h, β+ emission rate of 23%, low maximum energy of 0.9 MeV resulting in good spatial resolution, a stable daughter isotope of yttrium-
Dabkowski, Adam M. +3 more
core +3 more sources
89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors [PDF]
, 2012 The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases.
Chang, Albert J. +5 more
core +3 more sources